0
Original Research: SLEEP MEDICINE |

Relationship Between β-Blocker Treatment and the Severity of Central Sleep Apnea in Chronic Heart Failure*

Akira Tamura, MD; Yoshiyuki Kawano, MD; Shigeru Naono, MD; Munenori Kotoku, MD; Jun-ichi Kadota, MD, PhD
Author and Funding Information

*From the Second Department of Internal Medicine, Faculty of Medicine, Oita University, Oita, Japan.

Correspondence to: Akira Tamura, MD, Second Department of Internal Medicine, Faculty of Medicine, Oita University, Hasama, Yufu, Oita 879-5593, Japan; e-mail: akira@med.oita-u.ac.jp



Chest. 2007;131(1):130-135. doi:10.1378/chest.06-0919
Text Size: A A A
Published online

Background: We sought to examine the relationship between use of β-blockers and the severity of central sleep apnea (CSA) in patients with chronic heart failure.

Methods: We performed polysomnography in 45 patients with chronic heart failure (New York Heart Association functional class II/III and left ventricular ejection fraction < 50%) and examined the relationship between use of β-blockers and the severity of CSA. Central apnea index (CAI) was used as an indicator of CSA.

Results: Patients receiving β-blockers (ie, carvedilol; n = 27) had lower apnea-hypopnea index (AHI) and CAI than patients not receiving β-blockers (n = 18) [mean ± SD, 14 ± 11 vs 33 ± 17, p < 0.0001; and 1.9 ± 3.2 vs 11 ± 12, p = 0.0004, respectively]. AHI and CAI were negatively correlated with the dose of carvedilol (Spearman ρ = − 0.61, p < 0.0001; and Spearman ρ = − 0.57, p = 0.0002, respectively). Multiple regression analysis selected no use of β-blockers as an independent factor of CAI (p = 0.0006). In five patients with CAI > 5 who underwent serial sleep studies, CAI decreased significantly after 6 months of treatment with carvedilol (9.5 ± 4.9 to 1.3 ± 2.4, p = 0.03).

Conclusions: In patients with chronic heart failure, CAI was lower according to the dose of β-blockers, and no use of β-blockers was independently associated with CAI. In addition, 6 months of treatment with carvedilol decreased CAI. These results suggest that β-blocker therapy may dose-dependently suppress CSA in patients with chronic heart failure.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543